title: [Advances in the Treatment of Relapsed Small Cell Lung Cancer].
abstract: Small cell lung cancer (SCLC) is a highly malignant tumor. The initial treatment of radiotherapy and chemotherapy are more sensitive, high remission rate, but susceptible to drug resistance and relapse after treatment. Although the treatment of lung cancer has undergone enormous changes in recent years, treatment for relapsed SCLC is still a difficult problem in clinical field. In view of the serious resistance of recurrent SCLC to the existing chemotherapeutic drugs, the research on recurrent SCLC around the world is focused on the clinical trial of new drug development, optimization of chemotherapy regimen and target drug development. This paper summarize and estimate studies and literature reports of chemotherapy and precision therapy for relapsed SCLC, hopefully it could help clinicians treat relapsed SCLC and give us clinical research direction for relapsed SCLC in the future.
authors.affiliation: Department of Respiratory and Critical Care, Tianjin Chest Hospital, Tianjin 300222, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Liu
authors.affiliation: Department of Respiratory and Critical Care, Tianjin Chest Hospital, Tianjin 300222, China.
authors.forename: Jianwen
authors.initials: J
authors.lastname: Qin
authors.affiliation: Department of Respiratory and Critical Care, Tianjin Chest Hospital, Tianjin 300222, China.
authors.forename: Jingmin
authors.initials: J
authors.lastname: Zhou
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000628:therapy*; D057285:Precision Medicine; D012008:Recurrence; D055752:Small Cell Lung Carcinoma / Q000098:blood supply / Q000188:drug therapy / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors